Bone marrow smears and flow cytometry suggested possible MDS; however, genetic testing identified compound heterozygous pathogenic variants in the <i>TCN2</i> gene, confirming <i>TCN2</i> deficiency. The gene discussed is TCN2; the disease is myelodysplastic syndrome.